Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer
10.1126/scitranslmed.3007205
Saved in:
Main Authors: | Yasuda, H., Park, E., Yun, C.-H., Sng, N.J., Lucena-Araujo, A.R., Yeo, W.-L., Huberman, M.S., Cohen, D.W., Nakayama, S., Ishioka, K., Yamaguchi, N., Hanna, M., Oxnard, G.R., Lathan, C.S., Moran, T., Sequist, L.V., Chaft, J.E., Riely, G.J., Arcila, M.E., Soo, R.A., Meyerson, M., Eck, M.J., Kobayashi, S.S., Costa, D.B. |
---|---|
Other Authors: | CANCER SCIENCE INSTITUTE OF SINGAPORE |
Format: | Article |
Published: |
2014
|
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/117165 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
EGFR exon 20 insertion A763-Y764insFQEA and response to erlotinib-letter
by: Voon, P.J., et al.
Published: (2014) -
PERBANDINGAN RESPONS TERAPI GEFITINIB PADA PASIEN KPKBSK
DENGAN EGFR MUTASI EXON 19 DAN EXON 21
by: Titin Sholihah Agustina, NIM011180901
Published: (2017) -
Missense mutations in exons 18-24 of EGFR in hepatocellular carcinoma tissues
by: Ravat Panvichian, et al.
Published: (2018) -
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations
by: Costa D.B., et al.
Published: (2018) -
Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
by: Yeo, W.-L., et al.
Published: (2011)